RCT | Rivaroxaban prophylaxis in noncirrhotic portal vein thrombosis.
2 Dec, 2022 | 14:24h | UTCRivaroxaban Prophylaxis in Noncirrhotic Portal Vein Thrombosis – NEJM Evidence
Commentary on Twitter
This #RCT examined the use of rivaroxaban to reduce risk of venous thromboembolism (VTE) in pts with non-cirrhotic chronic portal vein thrombosis (PVT). Daily rivaroxaban reduced incidence of VTE and did not increase major bleeding events. https://t.co/CbenUb8ZWz#LiverTwitter pic.twitter.com/bgN1QS171j
— NEJM Evidence (@NEJMEvidence) November 22, 2022